ANALISA HUNT: Open Payments
NPI 1639848468 · LA JOLLA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,500 in 132 payments from 20 companies in 2025. Trend: 2023 $1,461 · 2024 $2,773 · 2025 $3,500
Food & beverage: $3,483Education: $17
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 27 | $737 |
| AstraZeneca Pharmaceuticals LP | 12 | $422 |
| GENZYME CORPORATION | 9 | $345 |
| Amgen Inc. | 12 | $322 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $255 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $255 |
| LEO Pharma Inc. | 14 | $249 |
| Grifols USA, LLC | 10 | $188 |
| PFIZER INC. | 6 | $149 |
| Regeneron Healthcare Solutions, Inc. | 4 | $117 |
Products named: TEZSPIRE, NUCALA, DUPIXENT, NEFFY, ADBRY, TRELEGY ELLIPTA, Xembify, CIBINQO.
Industry payments across CA — which companies pay providers there.
